level-one heading

Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 80 /hr
Hire Dr. Eleonora P.
Switzerland
USD 80 /hr

PhD Molecular Biologist | Biomedical Research | Medical Writing | Scientific Consulting | AI Evaluation

Profile Summary
Subject Matter Expertise
Services
Writing Clinical Trial Documentation, Medical Writing, General Proofreading & Editing
Research Meta-Research, Technology Scouting, Fact Checking, Gray Literature Search, Scientific and Technical Research, Systematic Literature Review
Consulting Healthcare Consulting, Scientific and Technical Consulting
Data & AI Image Analysis, Text Mining & Analytics, Data Insights
Product Development Product Evaluation
Work Experience

University of Zurich

January 2015 - Present

Senior Research Scientist

University of Zurich (UZH), Zurich, Switzerland

January 2015 - September 2021

Postdoctoral Researcher

University of Bern

November 2005 - January 2015

Education

PhD-Life Sciences

Friedrich-Alexander Universität Erlangen-Nürnberg - Germany

January 2002 - May 2005

Certifications
  • Certification details not provided.
Publications
JOURNAL ARTICLE
Eleonora Patsenker, Veera Raghavan Thangapandi, Oskar Knittelfelder, Alessandra Palladini, Michaela Hefti, Jane Beil-Wagner, Gerhard Rogler, Thorsten Buch, Andrej Shevchenko, Jochen Hampe, et al.(2022). The PNPLA3 variant I148M reveals protective effects toward hepatocellular carcinoma in mice via restoration of omega-3 polyunsaturated fats . The Journal of Nutritional Biochemistry. 108. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 109081. Elsevier {BV}
Weder B, Schefer F, van Haaften WT, Patsenker E, Stickel F, Mueller S, Hutter S, Schuler C, Baebler K, Wang Y, et al.(2022). New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4 . Inflammatory bowel diseases.
Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vvedenskaya O, Buch S, Hinz S, Hendricks A, Nati M, Herrmann A, et al.(2020). Loss of hepatic Mboat7 leads to liver fibrosis . Gut.
Moncsek A, Al-Suraih MS, Trussoni CE, O&#39;Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, et al.(2017). Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2<sup>-/-</sup> ) mice . Hepatology (Baltimore, Md.).
Patsenker E, Chicca A, Petrucci V, Moghadamrad S, de Gottardi A, Hampe J, Gertsch J, Semmo N, Stickel F(2017). 4-O'-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice . Journal of molecular medicine (Berlin, Germany).
Dondorf F, Fahrner R, Ardelt M, Patsenker E, Stickel F, Dahmen U, Settmacher U, Rauchfu&#223; F(2017). Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model . World journal of gastroenterology.
Patsenker E, Stickel F(2016). Cannabinoids in liver diseases . Clinical liver disease.
Mahli A, Thasler WE, Patsenker E, M&#252;ller S, Stickel F, M&#252;ller M, Seitz HK, Cederbaum AI, Hellerbrand C(2015). Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro . Oncotarget.
Patsenker E, Sachse P, Chicca A, Gachet MS, Schneider V, Mattsson J, Lanz C, Worni M, de Gottardi A, Semmo M, et al.(2015). Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation . International journal of molecular sciences.
Fahrner R, Patsenker E, de Gottardi A, Stickel F, Montani M, Stroka D, Candinas D, Beldi G(2014). Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy . Transplantation.
von Sch&#246;nfels W, Patsenker E, Fahrner R, Itzel T, Hinrichsen H, Brosch M, Erhart W, Gruodyte A, Vollnberg B, Richter K, et al.(2014). Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites . Liver international : official journal of the International Association for the Study of the Liver.
Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, S&#228;gesser H, Niedobitek G, Goodman SL, Schuppan D(2009). Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis . Hepatology (Baltimore, Md.).
Wang Y, Millonig G, Nair J, Patsenker E, Stickel F, Mueller S, Bartsch H, Seitz HK(2009). Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease . Hepatology (Baltimore, Md.).
Stickel F, Droz S, Patsenker E, B&#246;gli-Stuber K, Aebi B, Leib SL(2008). Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis . Journal of hepatology.
Lukivskaya O, Patsenker E, Lis R, Buko VU(2008). Inhibition of inducible nitric oxide synthase activity prevents liver recovery in rat thioacetamide-induced fibrosis reversal . European journal of clinical investigation.
Stickel F, Osterreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, Patsenker E, Schneider V, Kolb A, Friess H, et al.(2008). No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease . Alcoholism, clinical and experimental research.
Osterreicher CH, Halangk J, Berg T, Patsenker E, Homann N, Hellerbrand C, Seitz HK, Eurich D, Stickel F(2008). Evaluation of the transforming growth factor beta1 codon 25 (Arg-->Pro) polymorphism in alcoholic liver disease . Cytokine.
Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D(2008). Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies . Journal of hepatology.
Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D(2006). Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB . The Journal of biological chemistry.
Li ZD, Bork JP, Krueger B, Patsenker E, Schulze-Krebs A, Hahn EG, Schuppan D(2005). VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase . Biochemical and biophysical research communications.
Stickel F, Patsenker E, Schuppan D(2005). Herbal hepatotoxicity . Journal of hepatology.
Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D(2005). Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes . Journal of hepatology.
Dan Z, Popov Y, Patsenker E, Preimel D, Liu C, Wang XD, Seitz HK, Schuppan D, Stickel F(2005). Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential . FASEB journal : official publication of the Federation of American Societies for Experimental Biology.